What PEG-MGF is claimed to be
PEG-MGF is a market name for a polyethylene-glycol-modified peptide related to the E-domain of an IGF-1 splice variant often called mechano growth factor. It is not the same thing as the IGF1 transcripts naturally measured in muscle, and there is no FDA-approved PEG-MGF product, formulation, indication, or dose.
The evidence is indirect
Human exercise studies have measured changes in endogenous IGF-1 splice-variant expression in muscle biopsies.[1] Those observations do not test an administered PEG-MGF product. Teloryx found no controlled human efficacy trial establishing PEG-MGF for muscle gain, recovery, healing, fat loss, or performance.
PEGylation can change a molecule's clearance and immune behavior. It does not prove that a vendor product has the intended structure, reaches muscle, reproduces local IGF-1 biology, or improves a clinical outcome.
FDA identifies specific formulation risks
FDA reports that compounded PEG-MGF may present immunogenicity risk for some routes and has complexities involving peptide impurities and active-ingredient characterization. FDA also states that it has not identified human exposure data for PEG-MGF drug products and lacks enough information to know whether they would cause harm.[2]
Compounded products are not FDA-approved or premarket-verified for safety, effectiveness, or quality.[3] There is no regulator-reviewed adverse-reaction table or long-term human safety program.
Regulatory and sport status
PEG-MGF is unapproved in the United States. Mechano growth factors and related growth-factor substances are prohibited in tested sport under the World Anti-Doping Agency list.[4] Teloryx does not publish a PEG-MGF dose, cycle, stack, or reconstitution recipe.